The innovative MicroCNX® Nano Series connectors help maintain sterility in CGT processes using 1/8- or 1/16-inch tubing and ...

Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors ...

Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his ...

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

Drug executives talked M&A and the incoming administration, but also weighed the outlook for cell and gene therapy developers ...

The company lost more than $3 billion in market value after cutting its forecast for 2025 revenue from its COVID-19 and RSV ...

Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research ...

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...